PDT Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

PDT Partners’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-27,445	Closed	-$1.92M	–	949
2022 Q3	$1.92M	Sell	27,445 -10,499	-28%	-$777K	0.29%	78
2022 Q2	$2.55M	Buy	+37,944	New	+$2.41M	0.22%	120
2021 Q1	–	Sell	-2,129	Closed	-$468K	–	911
2020 Q4	$468K	Buy	+2,129	New	+$460K	0.03%	459
2018 Q2	–	Sell	-24,015	Closed	-$737K	–	593
2018 Q1	$737K	Sell	24,015 -1,209	-5%	-$33.6K	0.02%	397
2017 Q4	$460K	Sell	25,224 -42,976	-63%	-$667K	0.01%	436
2017 Q3	$798K	Buy	68,200 +13,500	+25%	+$78.1K	0.03%	381
2017 Q2	$200K	Buy	+54,700	New	+$210K	0.01%	483
2016 Q1	–	Sell	-18,600	Closed	-$588K	–	608
2015 Q4	$588K	Hold	18,600	–	–	0.08%	267
2015 Q3	$640K	Buy	18,600 +9,648	+108%	+$292K	0.01%	843
2015 Q2	$282K	Buy	+8,952	New	+$264K	0.01%	1148

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

PDT Partners's MRTX Position: Q4 2022 in Review

PDT Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2022, closing a stake of 27,445 shares — an estimated $1.92M sold.

PDT Partners first reported a position in MRTX in Q2 2015 and held it in 10 quarters. The position peaked at $2.55M in Q2 2022. 233 funds tracked by Wall St. Rank hold MRTX as of Q4 2022.

PDT Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
PDT Partners sold 27,445 Mirati Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $1.92M.
PDT Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2015 and held it in 10 quarters.
PDT Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $2.55M in Q2 2022.
233 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2022.

Based on PDT Partners's 13F filing for Q4 2022, filed 14 Feb 2023.